The first-ever drug created specifically to combat postpartum depression was approved by the U.S. Food and Drug Administration (FDA) on Tuesday.

Zulresso, created by Sage Therapeutics, is an IV drug administered "as a continuous infusion" over the course of 60 hours, or two and a half days, the agency announced in a news release.


In a company-funded study of new mothers with moderate or severe postpartum depression, reportedly half the women given Zulresso had depression end within two and a half days — about double the rate of those in a comparison group given dummy treatments.


Getting the "baby blues" after childbirth is common, according to the Mayo Clinic. After childbirth, "most" new mothers experience a range of symptoms, including mood swings, crying, trouble sleeping and irritability.

But some other mothers experience stronger, more severe emotions that are considered postpartum depression.

Excessive crying, overwhelming fatigue, difficulty bonding with the newborn child, fear of being an inadequate mother or total hopelessness are symptoms connected to postpartum depression that medical officials say can develop within the first few weeks following childbirth, but can start earlier or later.

It affects around 400,000 American women a year and can be treated with antidepressants, which can take six to eight weeks to work and don't help everyone, or with counseling.

"Postpartum depression is a serious condition that, when severe, can be life-threatening. Women may experience thoughts about harming themselves or harming their child," Dr. Tiffany Farchione, of the FDA's Division of Psychiatry Products, stated in the news release.

Farchione added that, "Postpartum depression can also interfere with the maternal-infant bond. This approval marks the first time a drug has been specifically approved to treat postpartum depression, providing an important new treatment option."

Zulresso's active ingredient, brexanolone, mimics a derivative of the naturally occurring hormone progesterone, levels of which can plunge after childbirth. Sage Chief Executive Dr. Jeff Jnas says the infusion helps restore normal levels and emotions.

Sage said Zulresso will cost $34,000 without insurance, plus costs for staying in a hospital or infusion center. Whether the treatment gets covered by insurance is determined by each insurance company, which also sets the out-of-pocket costs, depending on the plan.

The company — which is developing a similar treatment in pill form — plans to begin selling the drug in late June.

Cosmo Insurance Agency is an independent insurance agency serving surrounding communities in New Jersey. Cosmo keeps its promise to assure an efficient and creative approach to the services we offer. Each of our clients experience a personalized and long-term relationship with us. Our New Jersey based team of health brokers guides our clients in helping them choose the most cost-effective options. By incorporating the latest in technology-based tools and laws on healthcare, employee benefits, life insurance and finance, we keep our clients up-to-date with the plans that encompass all of their needs, whether it is individual or group insurance. '






Share |

No Comments

Post a Comment
Required (Not Displayed)

All comments are moderated and stripped of HTML.
Submission Validation
Change the CAPTCHA codeSpeak the CAPTCHA code
Enter the Validation Code from above.
NOTICE: This blog and website are made available by the publisher for educational and informational purposes only. It is not be used as a substitute for competent insurance, legal, or tax advice from a licensed professional in your state. By using this blog site you understand that there is no broker client relationship between you and the blog and website publisher.
Blog Archive
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015

View Mobile Version
© Copyright. All rights reserved.
Powered by Insurance Website Builder